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Abstract
Metabolic abnormalities occur after traumatic brain injury (TBI). Glucose is conventionally regarded as the major energy
substrate, although lactate can also be an energy source. We compared 3-13C lactate metabolism in TBI with ‘‘normal’’
control brain and muscle, measuring 13C-glutamine enrichment to assess tricarboxylic acid (TCA) cycle metabolism.
Microdialysis catheters in brains of nine patients with severe TBI, five non-TBI brain surgical patients, and five resting
muscle (non-TBI) patients were perfused (24 h in brain, 8 h in muscle) with 8 mmol/L sodium 3-13C lactate. Micro-
dialysate analysis employed ISCUS and nuclear magnetic resonance. In TBI, with 3-13C lactate perfusion, microdialysate
glucose concentration increased nonsignificantly (mean +11.9%, p = 0.463), with significant increases ( p = 0.028) for
lactate (+174%), pyruvate (+35.8%), and lactate/pyruvate ratio (+101.8%). Microdialysate 13C-glutamine fractional en-
richments (median, interquartile range) were: for C4 5.1 (0–11.1) % in TBI and 5.7 (4.6–6.8) % in control brain, for C3 0
(0–5.0) % in TBI and 0 (0–0) % in control brain, and for C2 2.9 (0–5.7) % in TBI and 1.8 (0–3.4) % in control brain. 13C-
enrichments were not statistically different between TBI and control brain, showing both metabolize 3-13C lactate via
TCA cycle, in contrast to muscle. Several patients with TBI exhibited 13C-glutamine enrichment above the non-TBI
control range, suggesting lactate oxidative metabolism as a TBI ‘‘emergency option.’’
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Introduction
As an organ, the brain relies on glucose. Other potential en-ergy metabolites such as lactate, other monocarboxylic ac-
ids, and ketone bodies are taken up into the brain under certain
circumstances. Lactate, however, conventionally regarded as a
waste product of ‘‘anaerobic’’ metabolism, can also act as an en-
ergy source, although its importance is debated.1–4 At the cellular
level, however, there is an interchange of energy metabolites, and
lactate is postulated to act in this capacity. The best described
metabolic relationship between cells in the brain is the astrocyte-
neuron lactate shuttle (ANLS) hypothesis.4,5
The human brain can metabolize lactate via the tricarboxylic
acid (TCA) cycle, as shown by studies in animal6–8 and human
brain (healthy volunteers and those with traumatic brain injury
[TBI]).9–11 The study in human patients with TBI utilized micro-
dialysis catheters to perfuse 3-13C lactate into the brain.11 Sub-
sequent 13C nuclear magnetic resonance (NMR) analysis of
returned microdialysates revealed 13C labeling in the TCA cycle
derivatives glutamine and glutamate, thereby demonstrating that
the human injured brain can metabolize lactate through the TCA
cycle.11 The latter study was qualitative and did not quantify the
degree of metabolism.
Boumezbeur and associates9 showed, in healthy human volun-
teers’ brains, using intravenous 13C-lactate and in vivo 13C MRS of
brain, that lactate is oxidatively metabolized to 13C-labeled gluta-
mate/glutamine, hallmarks of TCA cycle operation. Glenn and
colleagues12 performed an indirect study of brain metabolism, us-
ing arteriovenous measurements of 13CO2 as evidence of brain
metabolism of 13C-lactate (given intravenously), in patients with
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TBI and healthy volunteers,12 but they did not undertake direct
measurements of the brain.
Lactate shows evidence of being neuroprotective in injured
brain.13–20 In particular, Bouzat and coworkers16 showed evidence
for beneficial effects resulting from intravenous lactate administra-
tion in patients with TBI. There were significant increases in brain
microdialysate lactate, pyruvate, and glucose. Reduction in brain
microdialysate glutamate and a significant reduction in intracranial
pressure (ICP) were also observed.16 The lactate solution admin-
istered was hypertonic, and it was not resolved how much of the
apparent benefit on ICP was because of this property or because of
the actual lactate itself.
Work by Ichai and colleagues21 in patients with TBI, however,
showed that hyperosmolar sodium lactate solution (504 mmol/L;
1100 mosm/L) given intravenously was more effective at lowering
ICP than a mannitol solution with an equivalent osmotic load (1160
mosm/L). Also, compared with saline (0.9%), a 0.5 mol/L sodium
lactate solution was more effective at reducing the occurrence of
raised ICP episodes in patients with TBI.22 Research by Quintard
and associates19 showed that the beneficial effect of intravenous
lactate on brain energetics (increasing brain extracellular glucose
concentration) was a characteristic of those TBI patients with a high
lactate/pyruvate ratio (>25) at baseline, rather than patients with
baseline ‘‘normal’’ lactate/pyruvate ratio (<25).19
The human TBI brain’s ability to oxidatively metabolize lactate
versus normal, uninjured human brain has hitherto been unexplored
directly. It is also unclear to what degree the TCA cycle in extra-
cranial organs and tissues can metabolize lactate compared with the
brain.
The aims of the present study were, therefore, to compare lactate
metabolism in TBI with ‘‘normal’’ (non-TBI) control brain and
resting muscle, and to quantify the production of glutamine iso-
topomers from lactate, to compare metabolism of lactate through
the TCA cycle in these different tissues.
Methods
Patients
Ethics. The protocol for this study was approved by the Na-
tional Research Ethics Service (NRES) Committee East of
England–Cambridge Central (REC Reference No. 11/EE/0463).
Informed consent was obtained from all participants in the control
‘‘normal’’ brain and muscle groups and assent from the relatives of
those patients who had TBI. None of the patients in this study
formed part of a previously published cohort. The study was per-
formed in conformation with the spirit and the letter of the De-
claration of Helsinki.
TBI brain microdialysis patients. Nine patients with TBI
were studied. Patients with TBI were defined as those who had
cranial trauma with consistent computed tomography scan findings
and required invasive intracranial monitoring as part of their clin-
ical management. Placements of microdialysis catheters in patients
with TBI were into white matter not close to focal lesions. Patients
were treated per local TBI-management protocols (including the
following in all patients: endotracheal intubation, ventilation, se-
dation, and muscular paralysis) as in a previous study.23
Control ‘‘normal’’ non-TBI brain microdialysis patients. Five
patients undergoing a craniotomy for the resection of a benign
lesion whereby a microdialysis catheter could be placed safely into
radiographically normal brain were selected as control subjects.
The microdialysis catheter was placed via the craniotomy at the
time of craniotomy under direct vision after resection of the benign
lesion and tunneled under the scalp. The catheters were inserted at
the edge of the craniotomy and directed away from the operative
site into white matter; they came to lie approximately 2–3 cm away
from the area of brain from which the benign lesion had been
resected. The control patients were awake for the duration of mi-
crodialysis perfusion.
Muscle microdialysis patients. Five patients undergoing
resections of acoustic neuromas that required thigh fat and fascia
harvesting for dural closure were recruited for studying resting
muscle. Microdialysis was performed as before, with patients under
general anesthesia for the duration of microdialysis perfusion.23
Materials
Central nervous system (CNS) perfusion fluid and T1 perfusion
fluid, the compositions of which were described previously,23 were
obtained from M Dialysis AB (Stockholm, Sweden). Sodium L-
lactate (3-13C) (isotopic enrichment 99%, chemical purity 99%,
microbiological and pyrogen tested MPT grade) 20% w/w in water
was obtained from Cambridge Isotope Laboratories, Inc. (Tewks-
bury, MA) and was formulated to a final concentration of 8 mmol/L
in CNS perfusion fluid (for brain) or T1 perfusion fluid (for muscle)
by the Manufacturing Unit, Department of Pharmacy, Ipswich
Hospital NHS Trust, who then tested the formulations to verify pu-
rity, sterility, freedom from endotoxins. and absence of pyrogenicity.
Microdialysis technique
The microdialysis technique and catheters (M Dialysis 71) were
the same as before.23 Catheters were placed into the right frontal
white matter via a triple lumen cranial access device (Technicam,
Newton Abbot, Devon, UK) in locations not close to focal lesions
in the patients with TBI. Each patient received one microdialy-
sis catheter, except for one patient with TBI in whom a left frontal
catheter was placed via a craniotomy in addition to a right frontal
catheter via cranial access device (Table 1). Catheters in the pa-
tients with TBI and the ‘‘normal’’ (non-TBI) brain control subjects
were perfused with CNS perfusion fluid supplemented with sodium
3-13C lactate (8 mmol/L) at 0.3 lL/min. In resting muscle, catheters
were perfused with T1 perfusion fluid supplemented with sodium
3-13C lactate (8 mmol/L) at 0.3 lL/min. Microdialysate collection
vials from the patients with TBI were changed hourly and analyzed
at the bedside using an ISCUS analyzer (M Dialysis AB) em-
ploying enzymatic colorimetric assays for glucose, lactate, pyru-
vate, and glutamate. In patients with TBI, brain tissue oxygen
tension (PbtO2) data were collected using a Licox brain tissue
oxygen sensor (GMS, Kiel-Mielkendorf, Germany) placed via the
same cranial access device as the microdialysis catheter, and re-
corded at the bedside using ICM+ software (Cambridge Enterprise
Ltd, University of Cambridge, UK).
NMR analysis
Microdialysate sample preparation and NMR analysis were per-
formed as before.23 Brain microdialysate samples were pooled into
24-h periods for each patient. For NMR analysis, 20lL of deuterium
oxide (D2O) and 50lL internal reference standard from a stock
solution of 24.0 mmol/L 3-(trimethylsilyl)-1-propanesulfonic acid
sodium salt (also termed 2,2-dimethyl-2-silapentane-5-sulfonate
sodium salt or 4,4-dimethyl-4-silapentane-1-sulfonate sodium salt;
DSS) in CNS perfusion fluid were added to 180 lL of the pooled
microdialysate sample. Muscle microdialysate samples were
pooled into 8-h periods for each patient, these shorter periods
(compared with 24-h pool for each brain patient) being because of
clinical constraints. Then 20lL of D2O and 70lL from a stock
solution of 2.84 mmol/L DSS were added to 120lL of the pooled
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microdialysate sample. Pooled samples, after addition of D2O and
DSS, were stored at -80C. For NMR analysis, samples were
transferred into 3 mm NMR tubes (Hilgenberg GmbH, Malsfeld,
Germany). All chemical shifts were referenced to DSS = zero ppm
(Hz per MHz) in the NMR spectra.
The 13C and 1H NMR spectra were acquired as described pre-
viously23 on a Bruker Avance III HD 500 MHz spectrometer
(Bruker BioSpin GmbH, Karlsruhe, Germany) with a dual 13C/1H
cryoprobe (CP DUL500C/H, Bruker BioSpin GmbH), and TopSpin
software (Bruker GmbH). using the pulse programs noesypr1d and
zgpg30 for 1H and 13C spectra, respectively.23 These are detailed
Supplementary Methods (see online supplementary material at ftp.
liebertpub.com). Because of the small sample size of the micro-
dialysates, which necessitated long acquisition times to achieve
adequate sensitivity, it was impracticable to run fully relaxed
spectra without nuclear Overhauser enhancement. Therefore, we
undertook detailed calibration of the signal intensities for each
carbon position within the glutamine molecule (see paragraph be-
low on quantification).
Interpretation of the NMR results was based on biosynthetic
pathways summarized schematically in Figure 1, which shows the
glutamine labeling patterns corresponding to TCA cycle metabo-
lism of lactate. To summarize, 3-13C lactate is metabolized via
pyruvate dehydrogenase (PDH) to 4-13C glutamine on the first turn
of the TCA cycle and to equal amounts of 2-13C glutamine and
3-13C glutamine on the second turn of the TCA cycle. When 3-13C
lactate is metabolized via pyruvate carboxylase (PC), 2-13C glu-
tamine is produced on the first turn of the TCA cycle.
Quantification of glutamine isotopomers was performed with the
same methodology used previously.24 Calibration curves were
constructed using glutamine standards of varying concentration
prepared in CNS perfusion fluid with the same fixed concentration
of D2O and DSS used for the preparation of brain microdialysate
samples and run under identical NMR conditions. The peak areas
(measured using TopSpin software) of the glutamine 13C NMR
signals in the microdialysate samples relative to the DSS internal
standard were used with reference to the calibration curves to
calculate 13C concentration. Notably, the 13C NMR signals of each
of the glutamine carbon positions (C2, C3, C4) were individually
calibrated, thereby taking into account the different strengths of
nuclear Overhauser enhancement effect at these individual posi-
tions. Peak areas of the 1H NMR spectra fitted using Chenomx
software (Chenomx Inc, Edmonton, Canada) were used to calculate
12C concentration.
Fractional enrichment (%) is defined as 100 · [13C] / ([13C] +
[12C]) where square brackets indicate concentrations of the relevant
species. [13C] was determined from the 13C NMR spectra and [12C]
from the 1H spectra. Natural abundance of 13C is 1.1% of all carbon
atoms, and 13C fractional enrichment values for glutamine were
expressed after subtracting this naturally occurring 13C background
from the 13C singlet signals.
Statistical analysis
Statistical analyses were performed using SPSS21 for Mac (IBM
SPSS Statistics, NY). Changes of ISCUS microdialysis parameters
between baseline and 3-13C lactate perfusion periods were assessed
for statistical significance with Wilcoxon signed rank test with a
preselected p value of 0.05 for statistical significance. Student
paired t test (StatView 5, SAS Institute, Cary, NC) was used ad-
ditionally for corroboration. Mann-Whitney U test (on SPSS21)
was used to compare glutamine fractional enrichment between TBI
and normal brain microdialysates.
Results
Demography
Nine patients with severe TBI (eight male, one female) aged 22–
64 years (median 45 years) were studied using 3-13C lactate
(8 mmol/L) perfusion via the microdialysis catheter for 24 h. Eight
of the nine patients had simultaneous collection of microdialysates
for NMR analysis. One of these patients had 3-13C lactate perfusion
via bilateral catheters: one catheter placed via a bolt (cranial access
device) into right frontal white matter and the other catheter via
craniotomy into left frontal white matter. Apart from this one
craniotomy catheter, all other catheters were placed into the right
frontal white matter via a bolt that was not close to focal lesions.
Microdialysis technique was in accord with the 2014 Consensus
Statement guidelines,25 so catheters were never placed in lesions,
and the first hour of microdialysate collected was never used for
clinical monitoring to eliminate any unreliable results from inser-
tion trauma and the pump flush sequence.
One patient underwent two 24-h periods of 3-13C lactate per-
fusion. Thus, a total of 10 samples from eight patients with TBI
underwent NMR analysis. Six of the nine patients with TBI also














(right frontal - RF;
left craniotomy - LC)
PbtO2 during
unsupple-mented period
and during 3-13C lactate
perfusion (mm Hg)
TBI 1 51 M Fall E1 V2 M5 MDU/GRL 14 RF & LC (2 catheters) –
TBI 2 36 M RTC E1 V1 M2 SDLx 34 & 60 RF 19.5, 29.3
TBI 3 17 M RTC E3 V4 M5 GRL 18 RF –
TBI 4 48 M Fall E4 V4 M5 SDL 26 RF –
TBI 5 45 M Assault – Vg* 64 RF –
TBI 6 22 F RTC E1 V2 M2 MDL 53 RF –, 23.9
TBI 7 24 M RTC E1 V1 M5 MDU 83 RF 27.9, 26.0
TBI 8 47 M RTC E1 V2 M5 SDL 37 RF 37.4, 31.4
TBI 9 64 M Fall E3 V4 M6 D 98 RF 20.2, 35.1
M, male; F, female; RTC, road traffic collision; GCS, Glasgow Coma Scale score (E, eye opening; V, verbal response; M, motor response. Maximum total
score= 15); PbtO2, brain tissue oxygen tension (median values), – not measured. In patients with RF catheter location, the microdialysis catheter and PbtO2 probe
were inserted via a triple lumen cranial access device into white matter. The LC (left craniotomy) microdialysis catheter (traumatic brain injury [TBI] patient 1)
was also in white matter. Clinical outcomes (categorized by Extended Glasgow Outcome Scale criteria): GRL, good recovery (lower); MDU, moderate disability
(upper); MDL, moderate disability (lower); SDL, severe disability (lower); Vg, vegetative; D, dead. x Outcome on transfer to rehabilitation hospital. *Outcome
on discharge from NCCU. Other outcomes were from clinic.
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underwent an unsupplemented microdialysis period with plain
CNS perfusion fluid (without 3-13C lactate). Demographic details
of the TBI patients are presented in Table 1, which includes
Glasgow Coma Scale (GCS) scores as a measure of initial severity
of the traumatic injury, and details of catheter placement.
As controls for comparison with the TBI brain, microdialysis
catheters were inserted in macroscopically normal-appearing brain
(frontal white matter), using the same 3-13C lactate (8 mmol/L)
perfusion at 0.3 ll/min, in five non-TBI patients (two male, three
female) aged 42–79 years (median 69 years) undergoing surgery
for benign brain tumors. Thigh (quadriceps, resting) muscle was
studied similarly in five other patients (two male, three female)
aged 59–68 years (median 61 years) undergoing surgery for
acoustic neuroma resection. Muscle microdialysis was limited to
periods of 8 h during which the patients were anesthetized under-
going acoustic neuroma surgery.
Bedside analysis
Unsupplemented microdialysis perfusion results were compared
with the 3-13C lactate perfusion period in patients with TBI. Mi-
crodialysate measurements (ISCUS analyzer) of glucose, lactate,
pyruvate, glutamate, and lactate/pyruvate ratio are shown in Fig-
ure 2 for six of the nine patients with TBI. The other three patients
with TBI who underwent 3-13C lactate microdialysis did not un-
dergo a period of unsupplemented perfusion fluid microdialysis.
Median values and interquartile ranges (IQRs) are shown for a 24-h
period with unsupplemented plain CNS perfusion fluid and for a
24-h period with 3-13C lactate perfusion (8 mmol/L).
As shown in Figure 2 (A-E), four of six patients demonstrated
increases and two of six patients decreases in glucose between an
unsupplemented microdialysis period (with plain CNS perfusion
fluid) and the 3-13C lactate perfusion period with a mean difference
of +11.9%. This increase was not significant ( p= 0.463). As ex-
pected, 3-13C lactate perfusion resulted in a significant increase in
microdialysate lactate ( p= 0.028); all patients demonstrated in-
creases in lactate between unsupplemented and 3-13C lactate per-
fusion periods with a mean difference of +174%. Pyruvate
increased significantly between unsupplemented and 3-13C lactate
perfusion period with a mean difference of 35.8% (p = 0.028). The
lactate/pyruvate ratio was also observed to rise significantly with a
mean difference of 101.8% ( p= 0.028). Glutamate concentrations
did not change significantly between unsupplemented and 3-13C
lactate perfusion periods with a mean difference of 51.1%
( p= 0.60).
These statistical comparisons were by Wilcoxon signed rank test
(a paired nonparametric test). These results were corroborated by
paired Student t test (a paired parametric test): glucose (nonsig-
nificant, p= 0.72), lactate (significant, p= 0.0003), pyruvate (sig-
nificant, p= 0.0108), lactate/pyruvate ratio (significant, p= 0.0078),
and glutamate (nonsignificant, p= 0.44).
PbtO2 (Fig. 2F) did not change significantly between un-
supplemented and 3-13C lactate perfusion periods, although com-
plete data were only available for four patients, two of whom
showed an increase and two a decline in PbtO2 during lactate
perfusion compared with unsupplemented perfusion (Wilcoxon
signed rank test, p= 0.47; paired Student t test p= 0.45).
Metabolic products derived from 3-13C lactate
Illustrative examples of 13C NMR spectra of the microdialysates
are shown in Figure 3. Resulting from 3-13C lactate perfusion, TBI
FIG. 1. Schematic of 13C labeling patterns derived from 3-13C lactate. 3-13C lactate is metabolized to 3-13C pyruvate, which then
enters the tricarboxylic acid (TCA) cycle via conversion to 2-13C acetyl CoA by pyruvate dehydrogenase (PDH) or via pyruvate
carboxylase (PC) to 3-13C oxaloacetate. 2-13C acetyl CoA is metabolized to citrate, isocitrate, and then to 4-13C a-ketoglutarate where it
can then spin out as 4-13C glutamate, which is then converted to 4-13C glutamine. Consequently 4-13C glutamine is produced on the first
turn of the TCA cycle. If 4-13C a-ketoglutarate remains within the TCA cycle, it is metabolized to equal proportions of 2-13C malate and
3-13C malate because of ‘‘randomization’’ of label in the fumarate to malate step, because fumarate is a symmetrical molecule whereas
malate is asymmetric. If malate continues within the TCA cycle, equal amounts of 2-13C glutamine and 3-13C glutamine are produced
on the ‘‘second turn’’ of the TCA cycle. When 3-13C lactate is metabolized via PC to 3-13C oxaloacetate, 2-13C a-ketoglutarate is
produced, which results in 2-13C glutamine produced on the ‘‘first turn’’ of the TCA cycle. For the labeling patterns of the second turn,
we have assumed for schematic illustration that the incoming second acetyl-CoA molecule is not enriched with 13C. These patterns were
consistent with our observations; see Results section and Supplementary Table 2. Colored filled circles indicate position of 13C atoms
within molecules. Red indicates entry via PDH into the TCA cycle, first turn, and purple for second turn; yellow indicates entry via PC,
first turn.
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FIG. 2. ISCUS microdialysate and brain tissue oxygen tension (PbtO2) data for unsupplemented perfusion period versus 3-
13C lactate
(8 mmol/L) perfusion in patients with traumatic brain injury (TBI). (A–E) ISCUS clinical microdialysis analyzer measurements and (F)
PbtO2 data: during a 24-h period with unsupplemented plain CNS perfusion fluid and during 24 h perfusion with 3-
13C lactate (8 mmol/L).
Error bars represent interquartile ranges. ISCUS data are presented numerically in Supplementary Table 1 and PbtO2 values in Table 1.
FIG. 3. Illustrative examples of 13C nuclear magnetic resonance spectra for microdialysates from patients who received perfusion with
3-13C lactate. Traumatic brain injury (TBI) brain (uppermost two spectra, 24 h perfusion; patients TBI 1 and TBI 2, respectively), control
(non-TBI) ‘‘normal’’ brain (third spectrum, 24 h perfusion; patient CB 2), and muscle (fifth spectrum, 8 h perfusion). An example of brain
microdialysate from an unlabeled TBI patient with plain (unsupplemented) perfusion fluid is shown for comparison (fourth spectrum). Blue
arrows indicate pyruvate C3 enrichment, and orange arrows indicate glutamine C4, C3, and C2 enrichment. DSS, 4,4-dimethyl-4-silapentane-
1-sulfonate sodium salt (the internal reference standard); Glc, glucose; Gln, glutamine; Lac, lactate; Pyr, pyruvate, Ala, alanine. Spectra were
run from -20 ppm to +250 ppm. The main reference DSS signal at 0 ppm is not shown in the range illustrated. All chemical shift values (ppm,
on x-axis of spectrum) are relative to DSS at 0 ppm. The sixth spectrum is a standard solution consisting of a mixture of 1,2-13C2 glucose
(2 mmol/L) and 3-13C lactate (4 mmol/L) in central nervous system perfusion fluid showing the signals produced by these substrates.
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brain, ‘‘normal’’ (non-TBI) control brain, and muscle microdia-
lysates included clearly visible additional peaks, distinct from the
lactate peaks. These additional peaks were not visible in micro-
dialysates from patients receiving unsupplemented perfusion fluid
(unlabeled patient in Fig. 3), indicating cellular uptake and metabolism
of the 3-13C lactate. The substrate lactate C3 at 22.8 ppm produced the
largest signal as expected.
A clearly visible singlet peak at 29.2 ppm for pyruvate C3, which
was not visible in unlabeled TBI microdialysates, was present in TBI
brain, ‘‘normal’’ non-TBI control brain, and muscle microdialysates as
a result of 3-13C lactate perfusion. No other 13C pyruvate isotopomers
were detected. In our muscle microdialysates, a 13C NMR signal at
19.3 ppm corresponding to alanine C3 was observed (Fig. 3), although
we did not quantify enrichment. Identity of the alanine C3 was cor-
roborated by 1H–13C heteronuclear single quantum correlation.
Labeling of glutamine derived from 3-13C lactate was detected
in seven of 10 TBI and four of five ‘‘normal’’ (non-TBI) control
brain microdialysates, but not in muscle. In the patients with TBI,
glutamine labeling was detected in the C4 position (33.7 ppm) in
six of 10 samples, in the C2 position (57.1 ppm) in six of 10 sam-
ples, and in the C3 position (30.0 ppm) in four of 10 samples. In
‘‘normal’’ non-TBI control brain microdialysates, C4 labeling was
detected in four of five, C2 labeling in three of five, and C3 labeling
in one patient. See Figure 4 for further details.
The greater fractional enrichment of glutamine C4 over C2 en-
richment indicates that the entry of 13C to the TCA cycle was
predominantly via PDH rather than PC. The reason is that when
3-13C lactate enters the TCA cycle via PDH, it produces labeling at
C4 of glutamine on the first turn (and C2 and C3 glutamine iso-
topomers only on subsequent turns), whereas if 3-13C lactate enters
the TCA cycle via PC, it leads to labeling on C2 of glutamine on the
first turn of the TCA cycle (see Fig. 1). In only one of the patients
(TBI patient 3) was C2 labeling greater than C4, and in this patient,
C4 labeling was undetectable above background.
Overall, there were no statistically significant differences between
TBI and ‘‘normal’’ non-TBI control brain microdialysates for glu-
tamine fractional enrichment values for C4, C3, or C2 isotopomers
(Fig. 4, 5, and Supplementary Table 2; see online supplementary
material at ftp.liebertpub.com). C4 glutamine fractional enrichment
(median and IQR) was 5.1 (0–11.1) % in TBI and 5.7 (4.6–6.8) % in
the non-TBI control brain. C3 enrichment was 0 (0–5.0) % in TBI and
0 (0–0) % in the non-TBI control brain. C2 enrichment was 2.9 (0–5.
7) % in TBI and 1.8 (0–3.4) % in the non-TBI control brain. All of the
above enrichments in glutamine were in the form of single labeling.
Double-labeling was not detected in glutamine, evidenced by the
absence of 13C NMR doublet signals (for further details, see footnote
to Supplementary Table 2). No glutamine enrichment above that
expected from natural abundance 13C was detected in muscle mi-
crodialysates.
Discussion
In this study, 3-13C lactate microdialysis of human muscle and
brain with subsequent 13C NMR analysis of microdialysates dem-
onstrated TCA cycle metabolism of lactate to glutamine in the brain
but not muscle, although muscle metabolized lactate to pyruvate.
The TCA cycle metabolism of lactate produced similar amounts
of glutamine in ‘‘normal’’ (non-TBI) control and injured brain.
Inspecting the glutamine labeling pattern revealed that the principal
entry of lactate to the TCA cycle was via PDH.
FIG. 4. 13C labeling of glutamine isotopomers. 13C fractional enrichment (%) values in the glutamine isotopomers C4, C3, and C2
(after subtraction of the 1.1% natural abundance background) in patients with traumatic brain injury (TBI) and control (non-TBI)
‘‘normal’’ brain patients. Four other patients (TBI 4, TBI 6, and TBI 7 and CB 4) showed no detectable 13C enrichment above natural
abundance background, and therefore are not illustrated. RF, right frontal; LC, left craniotomy; CB, control brain; (i) and (ii), first and
second periods of microdialysis, respectively. All the above 13C fractional enrichments in glutamine were in the form of single labeling.
Double-labeling was not detected in glutamine. For further details, see Table 1 and Supplementary Table 2.
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Labeling of glutamine indicates operation
of the TCA cycle
This study adds further evidence in support of lactate acting as an
oxidative energy substrate in the human brain. 3-13C lactate ad-
ministered to the brain by the microdialysis catheter resulted in the
production of glutamine (labeled at the C4, C3, and C2 positions),
which requires lactate to have been metabolized by the TCA cycle.
Detection of labeling in glutamine is a clear indicator of TCA
cycle metabolism of the labeled substrate. The reason is that a
portion of the TCA cycle intermediate a-ketoglutarate is converted
into the spinout product glutamate, which is enzymatically inter-
convertible with glutamine that dominates extracellularly. The
prevailing view of glutamate-glutamine cycling involves traffick-
ing between astrocytes and neurons. Glutamate is produced de novo
by the transamination of a-ketoglutarate, an intermediate of the
TCA cycle. Glutamate released from neurons during synaptic
transmission is taken up by astrocytes and converted to glutamine
by the action of glutamine synthetase, which is present predomi-
nantly in astrocytes. Glutamine is released by astrocytes into the
interstitial extracellular fluid, where it is imported by neurons and
converted to glutamate by phosphate-activated glutaminase. These
processes are known as the glutamate-glutamine cycle.26–30 Con-
sequently, carbons released from neurons during the synaptic re-
lease of glutamate are thus recycled to neurons in the form of
glutamine from astrocytes. Also, astrocytes/glia can themselves
synthesise glutamate de novo via the TCA cycle a-ketoglutarate
(see above) and the ensuing glutamate can be converted to gluta-
mine by the same astrocytes/glia.31,32
In summary, glutamine is derived from the TCA cycle either from
the transamination of a-ketoglutarate to produce glutamate, followed
by the action of glutamine synthetase in astrocytes, or following the
capture by astrocytes of leftover glutamate after neurotransmission.
Glutamate uptake by astrocytes is essential to terminate its effect as a
neurotransmitter and to prevent extracellular glutamate from reach-
ing excitotoxic levels.5 The present study indicates TCA cycle me-
tabolism of 3-13C lactate, because 13C signals for glutamine (C4, C3,
and C2) suggest that the TCA cycle is operating in the regions of
interest of the catheters, because glutamine is a product of glutamate
that is a spinout of the TCA cycle.
In muscle, uptake and metabolism of 3-13C lactate was evident by
the generation of 3-13C pyruvate and 3-13C alanine (Fig. 3). This is
consistent with literature reports that muscle can convert lactate to
pyruvate (by the action of lactate dehydrogenase), which is then
transaminated (by alanine aminotransferase) to form alanine,33 so
lactate C3 becomes pyruvate C3, which then becomes alanine C3, and
the process is reversible. Further downstream, metabolites of 3-13C
pyruvate in the form of TCA cycle intermediates were not detected in
muscle, in our study. The likelihood is that glutamine does not
function as an intercellular metabolite in resting muscle in the same
way as it does in brain. The fact that 3-13C lactate contributed to an
extracellular pool of pyruvate, however, indicates the activity of
FIG. 5. Microdialysate nuclear magnetic resonance (NMR) measurements of 13C labeling: glutamine enrichment. (A) Total glutamine
concentration measured using 1H NMR, in TBI brain, control (non-TBI) brain, and muscle. (B–D) Results from microdialysis perfusion
with 3-13C lactate (8 mmol/L) for 24 h in brain: TBI or control (non-TBI) ‘‘normal’’. Although glutamine was detectable in muscle
(measured using 1H NMR), 13C fractional enrichment of glutamine above natural abundance was not detectable in resting muscle. Natural
abundance of 13C was assumed to be 1.1%, and 13C fractional enrichment values for glutamine were expressed after subtracting this
naturally occurring 13C background. For patient identities, see Fig. 4 graph and legend. Data points depict individual measurements, and
bars indicate medians and interquartile ranges.
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lactate dehydrogenase in metabolizing lactate to pyruvate. This sug-
gests contribution of lactate to an intracellular pool of pyruvate that
could potentially undergo mitochondrial oxidative metabolism.
In resting muscle, however, we found no evidence to demon-
strate whether lactate contributes significantly to oxidative me-
tabolism. This may have been at least partly because of the shorter
periods that muscle underwent 3-13C lactate microdialysis (8 h,
because of clinical constraints), compared with brain 3-13C lactate
microdialysis (24 h) and to the fact that this muscle was resting. In
contrast, there is literature evidence that exercising muscle not only
produces lactate but also consumes and oxidizes lactate.34,35 Be-
cause of clinical limitations, we were unable to compare exercising
muscle with resting muscle in our own study.
TCA cycle metabolism of lactate occurs in both TBI
and non-TBI control brain
This quantitative study supports a previous 13C-labeling mi-
crodialysis study that demonstrated qualitatively the metabolism
of lactate via the TCA cycle in the injured human brain.11 In the
present study, we have quantified labeling (% enrichment) and
demonstrated that TCA cycle metabolism of lactate is not limited to
the injured brain but also occurs to a similar median degree in the
‘‘normal’’ (non-TBI) control brain. In the present study, no statis-
tically significant differences between TBI and non-TBI control
brain were observed for 13C enrichment values for any of the glu-
tamine isotopomers. Nevertheless, the upper range values for 13C
enrichment in glutamine were higher in TBI than non-TBI control
brain (see Fig. 5), which concur with the idea that in certain cases,
lactate oxidative metabolism via the TCA cycle is an ‘‘emergency
option’’ for injured brain. Several literature reports in other studies
support this idea.36,37 Our results are also compatible with the
ANLS hypothesis,4,5 although, of course, the lactate supply was
exogenous in our study, and our technique per se does not distin-
guish the cell-type(s) metabolizing the 3-13C lactate.
While lactate is often regarded as a neuronal substrate,4 astrocytes
have also been shown to oxidatively metabolize lactate via the TCA
cycle,38 albeit to a lower degree than neurons. Competition studies
in vitro, employing 1-13C glucose (with unlabeled lactate) and 3-13C
lactate (with unlabelled glucose) in neuronal cultures demonstrated
that lactate was preferentially consumed by the neurons for their
oxidative metabolism.39 In vivo, perfused 13C-lactate was considered
as mainly a neuronal substrate in both animals and humans (see
Introduction). These results are supported by the work of Ma¨chler
and coworkers,40 using the Laconic probe, showing a lactate gradient
from astrocytes to neurons, concentration of lactate being higher in
astrocytes (considered as a reservoir) than in neurons.
Oxidative metabolism of lactate via the TCA cycle is only
possible in the presence of adequate concentration of molecular
oxygen. The reason is that the TCA cycle is coupled to the mito-
chondrial electron transport chain (ETC), and the ETC requires
molecular oxygen to act as its terminal electron acceptor. The TCA
cycle itself does not use molecular oxygen; it utilizes NAD+ and
FADH as biochemical oxidizing agents that thereby become bio-
chemically reduced to form NADH and FADH2. Operation of the
ETC is essential to recycle NADH to recreate NAD+, and to recycle
FADH2 to recreate FADH, for the TCA cycle to continue to op-
erate. Without molecular oxygen, the ETC cannot function prop-
erly and therefore neither can the TCA cycle.
Of further note is that not all of our patients showed evidence of
lactate oxidative metabolism via the TCA cycle, evidenced by no
13C fractional enrichment in glutamine detectable above back-
ground in four subjects: three of the patients with TBI and one of
the ‘‘normal’’ (non-TBI) brain patients (Fig. 4 and Supplementary
Table 2). In all cases, we have presented fractional enrichment (%)
values after subtraction of the natural abundance background of 13C
that is 1.1% of all carbon atoms.
All the patients studied had detectable glutamine (Fig. 5A, total
glutamine concentration), but the apparent lack of 13C fractional
enrichment in glutamine above background for the four individuals
in question may indicate that lactate is not totally universal as a fuel
for brain cells. TBI patients four and six had baseline lactate/
pyruvate ratios >25 suggesting possible mitochondrial dysfunc-
tion in these patients. TBI patient four, however, had no available
PbtO2 data. In TBI patient six, PbtO2 was adequate (23.9 mm Hg)
during 3-13C lactate perfusion, supporting the theory that mito-
chondrial dysfunction was the reason for this patient’s lack of 13C
enrichment in glutamine.
Within the limitations of the small number of patients, there
were no other obvious distinguishing clinical features for these
nonresponders versus those who showed 13C enrichment in gluta-
mine. Interestingly, TBI patient seven, a nonresponder, had a
baseline lactate/pyruvate ratio median of 22.89 (IQR 22.48–23.76)
and PbtO2 well above 20 mm Hg both at baseline and during 3-
13C
lactate perfusion. Whether mitochondrial dysfunction can occur
despite the lactate/pyruvate ratio being somewhat below the con-
ventional threshold of 25 is an unanswered question.
A limitation of our study is that because its invasive nature, there
are no truly normal controls for cerebral microdialysis in humans.
In the present study, and in previous studies,23,24 we have been able
to perform microdialysis in radiologically normal brain areas in
non-TBI patients with benign tumors. In this context, this is the
closest to a normal control that can be achieved in human studies.
Patient considerations and practical matters, however, make such
sampling rare. Thus, it was not possible to achieve age- and sex-
matching between non-TBI brain controls and TBI subjects. Also,
in the present study, for the non-TBI brain controls, there was not
enough time to perform an unsupplemented microdialysis period,
because there was only sufficient time for microdialysis perfusion
with 3-13C lactate. Last, while we cannot entirely rule out the
possibility that surgery itself may constitute some degree of trauma,
we believe this is minor compared with the TBI cohort, given the
good clinical state of the postoperative non-TBI patients in com-
parison with the comatose TBI cohort in neurointensive care.
The issue of lesion progression is outside the scope of this study,
because it would have required dedicated imaging (e.g., magnetic
resonance imaging) before and after lactate delivery by micro-
dialysis. Our microdialysis catheters were not close to focal TBI
lesions (see Methods and Results sections). The rise in lactate/
pyruvate ratio (seen with 3-13C lactate perfusion, compared with an
unsupplemented perfusion period) was considered unlikely to be
linked to lesion progression, or vice versa, because the 13C labeling
showed that oxidative metabolism, evidenced by labeling in the
TCA cycle spinout product glutamine, was statistically not sig-
nificantly different in TBI brain and non-TBI control brain.
Effect of lactate on microdialysate markers and PbtO2
Administration of lactate to the extracellular space resulted in
significant increases in microdialysate pyruvate concentrations
measured on the ISCUS analyzer, which measures total levels re-
gardless of labeling. ISCUS measurements also showed, albeit
without statistical significance, an increase in glucose, consistent
with the idea of a glucose-sparing effect of lactate as a brain fuel.18
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The increase in pyruvate concentrations is as expected through
the action of lactate dehydrogenase. An alternative explanation for
the increase in pyruvate is that lactate causes increased delivery of
glucose to the cells with a subsequent increase in glycolytic pyru-
vate. Lactate is vasoactive and has been demonstrated both ex-
perimentally and in the human brain to increase cerebral blood flow
(CBF), mostly likely mediated via prostaglandins.41–43 Hence,
microdialysis perfusion with lactate might result in the increased
local delivery of glucose because of regional increases in CBF. This
might also be expected to increase PbtO2, which we observed in
two of four of the patients for whom we had complete PbtO2 data.
We believe, however, that the increase in pyruvate concentrations
is more likely to be a direct effect through lactate dehydrogenase
rather than a more circuitous mechanism through vascular reac-
tivity. This hypothesis (effect through lactate dehydrogenase) is
supported by the results of Quintard and colleagues.19
PDH versus pyruvate carboxylation
The 13C labeling of glutamine C4 indicates metabolism of 3-13C
lactate, by way of 3-13C pyruvate entry to the TCA cycle through
PDH (via 2-13C acetyl CoA) and synthesis of a-ketoglutarate dur-
ing the first turn that spins out to result in glutamine (Fig. 1). PDH is
part of the pyruvate dehydrogenase complex (PDC), the rate-
limiting step for pyruvate entry into the TCA cycle.44 All compo-
nents of the PDC are expressed in both neurons and astrocytes in
culture, but PDC activity is limited in astrocytes through phos-
phorylation of the PDH alpha subunit (PDHa).44 In contrast, neu-
ronal PDC operates at near-maximal levels with much lower levels
of phosphorylated PDHa.44 Dephosphorylation of astrocytic PDHa
increases PDC activity.44 Metabolism of astrocytes and neurons
thus appears flexible.44
In the present study, glutamine C4 exhibited the strongest 13C
enrichment of the glutamine isotopomers, indicating that overall
PDH was the predominant route for 3-13C lactate metabolism in the
brain, both TBI and ‘‘normal’’ (non-TBI) control (Fig. 4). Smaller
13C fractional enrichments were seen in glutamine C2 and C3,
consistent with the effect of the second TCA cycle turn after PDH
entry that produces a 1:1 mixture of 2-13C glutamine and 3-13C
glutamine, and the first turn of the TCA cycle after PC entry that
produces 2-13C glutamine (Fig. 4). Accordingly, 13C fractional
enrichment in glutamine C2 ‡ C3 in those control brain cases
showed enrichment in either or both of these positions. Unexpectedly,
two of the TBI cases showed 13C fractional enrichment at glutamine
C3 > C2 (see below for possible explanation). Overall in TBI, frac-
tional enrichments at glutamine C2 and C3 were not statistically
different from each other (Wilcoxon signed rank test p= 0.6, Stu-
dent paired t test p = 0.5). Also, as expected, glutamine C4 frac-
tional enrichment in patients with TBI was significantly higher than
at glutamine C3 (Wilcoxon signed rank test p= 0.0464; Student
paired t test p = 0.0484).
PC is a key enzyme for anaplerosis (topping up) of the TCA
cycle.45 PC is a mitochondrial enzyme regarded as glial rather than
neuronal.45 Because our microdialysis catheters were inserted into
white matter, they are likely to have encountered predominantly glia.
While lactate is regarded as a predominantly neuronal substrate, glia
can also oxidatively metabolize lactate to a lesser degree.46,47
Another potential anaplerotic route for 3-13C pyruvate into the
TCA cycle is via malic enzyme,45 found in both neurons and glia.
This would result, on first turn spinout, in a mixture of 2-13C glu-
tamine and 3-13C glutamine, the same pattern that would form on
the second turn if 3-13C pyruvate had entered the TCA cycle via
PDH. Malic enzyme can work reversibly.45 Previously, after ad-
ministration of 2,3-13C2 succinate by cerebral microdialysis in
patients with TBI, we found spinout of 2,3-13C2 lactate from the
TCA cycle, consistent with the action of malic enzyme.24 Whether
malic enzyme constitutes a significant anaplerotic (input) route into
the TCA cycle in the TBI or control brain remains a possibility.
Malic enzyme can also be involved in ‘‘scrambling’’ of 13C label
between pyruvate C3 and C2.48 3-13C pyruvate can enter the TCA
cycle via PDH and PC giving the established labeling patterns in
Fig 1. The 2-13C pyruvate entry to the TCA cycle via PDH, how-
ever, would give 5-13C glutamine (first turn) and loss of 13C label
(second turn). Moreover, 2-13C pyruvate entry to the TCA cycle via
PC would result in 3-13C glutamine (and not 2-13C glutamine).
Thus, label scrambling may contribute to the two TBI cases with
13C fractional enrichment in glutamine C3 > C2.
Differences between microdialysis delivery
of 13C-lactate and intravenous perfusion
The delivery and sampling method is a key difference between this
study, by microdialysis, which detected labeling in glutamine, and
earlier intravenous 13C-lactate perfusion studies (see Introduction),
which found labeling in glutamate. Moreover, intravenous 13C-
lactate perfusion studies assessed metabolite labeling patterns in
brain tissue, dominated by intracellular species, whereas mi-
crodialysis samples extracellular molecules. While glutamate is
abundant intracellularly in brain tissue (ca. 5–15 mmol/kg), its
concentration is typically low (ca. 1–20 lmol/L) in the extracel-
lular compartment of the brain, in which glutamine dominates (ca.
500 lmol/L).49,50
Glutamate is synthesized from the TCA cycle intermediate
alpha-ketoglutarate. Glutamate and glutamine are enzymatically
interconvertible; the mechanism involves glutamate-glutamine
cycling (trafficking) between neurons and astrocytes.11,49 Thus,
detection of the 13C label in glutamate and/or glutamine are hall-
marks of TCA cycle operation. In the present study, the finding of
glutamine labeling patterns indicative of both PDH and PC oper-
ation is consistent with the microdialysis location and consistent
with the fact that both delivery of 13C-lactate and the collection of
products were respectively to and from the extracellular compart-
ment of white matter.
Conclusion
We have shown that 3-13C lactate administered by microdialysis
is metabolized via the TCA cycle in both traumatically injured
brain and ‘‘normal’’ (non-TBI) control brain in human patients.
Lactate is initially metabolized to pyruvate, before entering the
TCA cycle mainly via PDH. Lactate administration leads to ele-
vated microdialysate concentrations of pyruvate. In muscle, evi-
dence of TCA cycle metabolism of lactate is lacking, although
lactate is metabolized to pyruvate. Based on the data in this study,
the hypothesis is accepted that the human brain, both traumatically
injured and non-TBI control, can oxidatively metabolize lactate.
We found no evidence, however, that resting muscle can oxida-
tively metabolize lactate. There was insufficient evidence to dif-
ferentiate statistically between the TBI and non-TBI control brain
for lactate metabolism via the TCA cycle. Nevertheless, the upper
range values for 13C enrichment in glutamine were higher in the
TBI brain than non-TBI control brain, which concur with the idea
that in certain TBI cases, lactate oxidative metabolism via the TCA
cycle can be an ‘‘emergency option’’ for the injured brain.
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